Every leftover from the last aisle sentence has a different object. Hostess is a bag on a shelf. Foundayo is a 1 April tablet. EMBRAZE is an 8 June paper about a kilogram that was not fat. Flatten those into one GLP trade and you get a false headline. Do not flatten them.
Pratley et al., Nat Med, 8 Jun 2026. EMBRAZE n=102, apitegromab 10 mg/kg q4w IV + tirzepatide. LSM −1.9 kg lean loss vs placebo (80% CI 1.2–2.7), 54.9% retention, p=0.001. NCT06445075. Scholar Rock print 18 Jun 2025.
A third of the weight off tirzepatide alone in that trial was lean mass.
Weight, fat, leftover
The dates are already on paper. 1 April on a Lilly approval. 8 June on a Nature Medicine letter. 18 June 2025 on the same 1.9 kilogram sentence, printed by the sponsor eleven months before the journal. A date is not a label.
EMBRAZE is the exposed paper
The letter the catalog actually produced is a Phase 2 composition result, not a product. Pratley, Denham, Trivedi and colleagues, Nature Medicine, 8 June 2026: EMBRAZE, 102 adults, tirzepatide plus apitegromab versus tirzepatide plus placebo. Apitegromab is a fully human monoclonal that selectively inhibits myostatin activation. Dose: 10 milligrams per kilogram every four weeks, intravenous. At week 24, least-squares mean 1.9 kilograms less lean-mass loss than placebo (80 percent CI 1.2 to 2.7; p = 0.001) despite similar total weight loss. Relative retention of lean mass: 54.9 percent. Adverse events 76 percent versus 71 percent. One serious event in each arm of 51. ClinicalTrials.gov NCT06445075. Scholar Rock funded it. The company had already printed the same 1.9 kilogram / 54.9 percent sentence on 18 June 2025. The journal made it a paper eleven months later.
The antibody did not make people lose more weight. It changed the composition of the same weight. That is the leftover. You can clear a calorie and still leave a sarcopenic year, a fall, a joint, a nurse. Bimagrumab BELIEVE, an activin-receptor antibody plus semaglutide, is the cousin in the same drawer. Enobosarm and the other myostatin and SARM notes are the rest of the drawer. None of them is approved for this use. Apitegromab is an SMA story that picked up an obesity sidecar. A Phase 2 of 102 people is a letter, not a cluster. It is also the first object that makes the leftover measurable.
Do not medicalise a ticker. Scholar Rock is a small listed name. Lilly and Novo are on the board because they sold the weight that created the kilogram. Stryker and Intuitive are the listed body-hardware cousins if you need a hip or a console. They are not EMBRAZE.
The food-demand page already named Hostess and Gallup's 11 percent. Units on a shelf are still the print. A 1.9 kilogram lean-mass delta is a different object. Foundayo shipped 1 April. That tablet is access. Figure's Forge print on 22 August was $174.00, down $20.93. That is a used share. The sink page already named Hefei, South Boston, Foundayo, and this 1.9 kilogram letter. This piece is the kilogram.
Tokens do not have lean mass. Watts do not. Orbits do not. Appetite did, and the industry is now writing antibodies against the waste product of its own drug. The tablet shipped. It is whoever owns the year the lighter body still has to live: muscle, bone, balance, care. A warehouse robot is the industrial version of the same sentence. One is a bid on replacing the hour. The other is a bid on keeping the hour from collapsing. Only one has a p-value.
What a paper cannot do
Cross-asset does not care which kilogram was kept. AI abundance cares only if the middle's hosting cost becomes a care cost. It has not, on the invoices those pages already named.
A refutation would look like this: a Phase 3 lean-mass preservation program, with a named antimyostatin or activin antibody plus an incretin, that has an NDA or a pre-announced filing date, by 31 December 2028, confirms the leftover became a product. A 2028 of Phase 2 letters and no filing confirms the kilogram stayed a paper. EMBRAZE is a trial, not a recommendation. The listed peers on the board for the weight are the incretin names, not the SMA name, until a 10-Q puts apitegromab in a sentence that can be dated.
The honest uncertainty is which object gets a number first. If a named Phase 3 files and Hostess is still a mix print, the kilogram moved and the aisle did not. If Hostess units fall and no antibody files, the aisle moved and the letter stayed a letter. If Foundayo prints a named line and EMBRAZE is still n=102, access shipped and the leftover did not. Those three sentences can live in the same year. One point nine kilograms are a fact about one paper. Eleven percent of adults are a fact about one survey. Neither is a label.
Copper coil in a steel basin.
Stamp and a jacket on the table.
Crane hook and a folded variance.
Breaker handle on an empty floor.